LEO Pharma pens $435m deal for Tanabe Pharma’s dersimelagon

LEO Pharma is betting up to $435m on a pill that could give people with an ultra-rare light sensitivity disorder a way to spend more time outdoors.

FDA turns down 'national priority' drug from Disc Medicine

One of the beneficiaries of the FDA's national priority vouchers, Disc Medicine, has had its marketing application turned down by the regulator.

Disc maps out US filing for porphyria drug bitopertin

Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA.

Clinuvel gets approval in US for rare skin disorder drug Sce...